Synergistic Activity of Trovafloxacin and Ceftriaxone or Vancomycin against Streptococcus pneumoniae with Various Penicillin Susceptibilities

While interest in Streptococcus pneumoniae has always been high because of its role as a frequent pathogen, the increasing prevalence of penicillin-resistant isolates is of growing concern (2, 9). Rising resistance rate coupled with the failure of monotherapy for meningitis due to these isolates now warrant that empirical therapy consist of ceftriaxone and vancomycin (5, 7, 8). Trovafloxacin, a new fluoroquinolone, has displayed exceptional activity against pneumococci and penetrates well into the cerebrospinal fluid (CSF) (1, 4). Although its role in treatment of pneumococcal meningitis is currently under investigation, its synergistic potential with currently utilized therapies is unknown.